Pharmacological correctors of mutant CFTR mistrafficking

Frontiers in Pharmacology

Volumn 3 OCT, Issue , 2012, Pages

  Pedemonte, Nicoletta ^a   Galietta, Luis J V ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

CFTR; Chloride channel; Cystic fibrosis; Drug discovery; Trafficking defect

Indexed keywords

BENZO[C]QUINOLIZINIUM; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HISTONE DEACETYLASE 7; IVACAFTOR; LUMACAFTOR; PHENYLALANINE; PHENYLHYDRAZONE DERIVATIVE; PROTEOME; RDR 1; SILDENAFIL; TRICYCLIC AROMATIC COMPOUND; UNCLASSIFIED DRUG;

ARTICLE; BIOCHEMICAL COMPOSITION; BRONCHUS MUCOSA; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; ENDOPLASMIC RETICULUM; HIGH THROUGHPUT SCREENING; HISTONE ACETYLATION; HUMAN; MOLECULAR DOCKING; MOLECULAR LIBRARY; MUTATIONAL ANALYSIS; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; STRUCTURE ANALYSIS;

EID: 84870735685     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00175     Document Type: Article

References (43)

1. Becq, E, Mettey, Y., Gray, M. A., Galietta, L. J., Dormer, R. L., Merten, M., et al. (1999). Development of substituted Benzo [c] quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. Biol. Chem. 274, 27415-27425.
2. Bobadilla, J. L., Macek, M. Jr., Fine, J. P., and Farrell, P. M. (2002). Cystic fibrosis: a worldwide analysis of CFTR mutations - correlation with incidence data and application to screening. Hum. Mutat. 19, 575-606.
3. Calamini, B., Silva, M. C, Madoux, F., Hutt, D. M., Khanna, S., Chalfant, M. A., et al. (2011). Small-molecule proteostasis regulators for protein conformational diseases. Nat. Chem. Biol. 8, 185-196.
4. Clancy, J. P., Rowe, S. M., Accurso, F. J., Aitken, M. L., Amin, R. S., Ashlock, M. A., et al. (2012). Results of a phase Ha study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTRmutation. Thorax 67, 12-18.
5. Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Dott, K., Dreyer, D., et al. (1991). Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354, 526-528.
6. Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., and Welsh, M. J. (1992). Processing of mutant cystic fibrosis trans-membrane conductance regulator is temperature-sensitive. Nature 358, 761-764.
7. Derand, R., Bulteau-Pignoux, L., Mettey, Y., Zegarra-Moran, O., Howell, L. D., Randak, C, et al. (2001). Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phos-phorylation. Am. J. Physiol 281, C1657-C1666.
8. Dormer, R. L, Derand, R., McNeilly, C. M., Mettey, Y, Bulteau-Pignoux, L, Metaye, T., et al. (2001). Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. Cell. Sci. 114,4073-4081.
9. Galietta, L. J., Springsteel, M. F., Eda, M., Niedzinski, E. J., By, K., Haddadin, M. J., et al. (2001). Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. Biol. Chem. 276, 19723-19728.
10. Gee, H. Y, Noh, S. H., Tang, B. L., Kim, K. H., and Lee, M. G. (2011). Rescue of AF508-CFTR trafficking via a GRASP-dependent unconventional secretion pathway. Cell 146, 746-760.
11. Grove, D. E., Rosser, M. E, Ren, H. Y, Naren, A. P., and Cyr, D. M. (2009). Mechanisms for rescue of correctable folding defects in CFTRDelta F508. Mol. Biol. Cell 20, 4059-4069.
12. Haws, C. M., Nepomuceno, I. B., Krouse, M. E., Wakelee, H., Law, T., Xia, Y, et al. (1996). AF508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am. J. Physiol. 270, C1544-C1555.
13. Hutt, D. M., Herman, D., Rodrigues, A. P., Noel, S., Pilewski, J. M., Matte-son, J., et al. (2010). Reduced his-tone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat. Chem. Biol. 6, 25-33.
14. Kalid, O., Mense, M., Fischman, S., Shitrit, A., Bihler, H., Ben-Zeev, E., et al. (2010). Small molecule correctors of AF508-CFTR discovered by structure-based virtual screening. Comput. Aided Mol. Des. 24, 971-991.
15. Lewis, H. A., Buchanan, S. G., Bur-ley, S. K., Conners, K., Dickey, M., Dorwart, M., et al. (2004). Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J. 23, 282-293.
16. Lewis, H. A., Zhao, X., Wang, C.,Sauder, J. M., Rooney, I., Noland, B. W., et al. (2005). Impact of the deltaF508 mutation in first nucleotide-binding domain of human cystic fibrosis transmembrane conductance regulator on domain folding and structure. Biol. Chem. 280, 1346-1353.
17. Lukacs, G. L., Chang, X. B., Bear, C, Kartner, N., Mohamed, A., Riordan, J. R., et al. (1993). The AF508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. Biol. Chem. 268,21592-21598.
18. Lukacs, G.L.,and Verkman,A.S. (2012). CFTR: folding, misfolding and correcting the (F508 conformational defect. Trends Mol Med. 18, 81-91.
19. Mendoza, J. L, Schmidt, A., Li, Q., Nuvaga, E., Barrett, T., Bridges, R. J., et al. (2012). Requirements for efficient correction of AF508 CFTR revealed by analyses of evolved sequences. Cell 148, 164-174.
20. 2+ level in the endo-plasmic reticulum restores abnormal endogenous F508del-CFTR traffickinsg in airway epithelial cells. Traffic 7, 562-573.
21. Norez, C, Noel, S., Wilke, M., Bijvelds, M., Jorna, H., Melin, P., et al. (2006b). Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett. 580,2081-2086.
22. Okiyoneda, T., Barriere, H., Bagdany, M., Rabeh, W. M., Du, K., Hohfeld, J., et al. (2010). Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329, 805-810.
23. Pedemonte, N., Lukacs, G. L., Du, K., Caci, E., Zegarra-Moran, O., Galietta, L. J., et al. (2005). Small-molecule correctors of defective AF508-CFTR cellular processing identified by high-throughput screening. Clin. Invest. 115, 2564-2571.
24. Pedemonte, N., Tomati, V., Sondo, E., Caci, E., Millo, E., Armirotti, A., et al. (2011). Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations. Biol Chem. 286, 15215-15226.
25. Pedemonte, N., Tomati, V., Sondo, E., and Galietta, L. J. (2010). Influence of cell background on pharmacological rescue of mutant CFTR. Am. J. Physiol 298, C866-C874.
26. Rabeh, W. M., Bossard, E, Xu, H., Okiyoneda, T., Bagdany, M., Mulvihill, C. M., et al. (2012). Correction of both NBD1 energetics and domain interface is required to restore AF508 CFTRfolding and function. Cell 148, 150-163.
27. Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C, Drevinek, P., etal. (2011).ACFTRpotentiatorin patients with cystic fibrosis and the G551D mutation. N. Engl. Med. 365,1663-1672.
28. Riordan, J. R. (2005). Assembly of functional CFTR chloride channels. Annu. Rev. Physiol. 67, 701-718
29. Riordan, J. R. (2008). CFTR function and prospects for therapy. Annu. Rev. Biochem. 77, 701-726.
30. Robert, R., Carlile, G. W., Pavel, C, Liu, N., Anjos, S. M., Liao, J., et al. (2008). Structural analog of silde-nafil identified as a novel corrector of the F508del-CFTR trafficking defect. Mol. Pharmacol. 73,478-489.
31. Rosenberg, M. E, O'Ryan, L. P., Hughes, G., Zhao, Z., Aleksandrov, L. A., Riordan, J. R., et al. (2011). The cystic fibrosis transmembrane conductance regulator (CFTR): three-dimensional structure and localization of a channel gate. Biol. Chem. 286, 42647-42654.
32. Sampson, H. M., Robert, R., Liao, J., Matthes, E., Carlile, G. W., Hanra-han, J. W., et al. (2011). Identification of a NBD1 -binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem. Biol. 18,231-242.
33. Sato.S., Ward, C.L.,Krouse,M.E., Wine, J. J., and Kopito, R. R. (1996). Glyc-erol reverses the misfolding pheno-type of the most common cystic fibrosis mutation. Biol. Chem. 271, 635-638.
34. Sheppard, D. N., Carson, M. R., Ost-edgaard, L. S., Denning, G. M., and Welsh, M. J. (1994). Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium. Am. J. Physiol. 266.L405-L413.
35. Sondo, E., Tomati, V., Caci, E., Espos-ito, A. I., Pfeffer, U., Pedemonte, N., et al. (2011). Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. Am. J. Physiol. 301, C872-C885.
36. Stratford, F. L., Pereira, M. M., Becq, E, McPherson, M. A., and Dormer, R. L. (2003). Benzo(c)quinolizinium drugs inhibit degradation of AF508-CFTR cytoplasmic domain. Biochem. Biophys. Res. Commun. 300,524-530.
37. Van Goor, F., Hadida, S., Grootenhuis, P. D., Burton, B., Cao, D., Neu-berger, T., et al. (2009). Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. U.S.A. 106, 18825-18830.
38. Van Goor, F., Hadida, S., Grootenhuis, P. D., Burton, B., Stack, J. H., Stra-ley, K. S., et al. (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investiga-tional drug VX-809. Proc. Natl. Acad. Sci. U.S.A. 108, 18843-18848.
39. Van Goor, F., Straley, K. S., Cao, D., Gonzalez, J., Hadida, S., Hazle-wood, A., et al. (2006). Rescue of AF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. 290, L1117-L1130.
40. Verkman, A. S., and Galietta, L. J. (2009). Chloride channels as drug targets. Nat. Rev. Drug Discov. 8, 153-171.
41. Verkman, A. S., Lukacs, G. L., and Galietta, L. J. (2006). CFTR chloride channel drug discovery - inhibitors as antidiarrheals and activators for therapy of cystic fibrosis. Curr. Pharm. Des. 12,2235-2247.
42. Younger, J. M., Chen, L, Ren, H. Y., Rosser, M. E, Turnbull, E. L, Fan, C. Y, et al. (2006). Sequential quality-control checkpoints triage misfolded cystic fibrosis transmem brane conductance regulator. Cell 126,571-582.
43. Zegarra-Moran, O., Romio, L., Folli, C, Caci, E., Becq, E, Vierfond, J. M., et al. (2002). Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Br. Pharmacol. 137,504-512.